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Migraine is the most common brain disorder, affecting approximately 14% of the adult
population, but its molecular mechanisms are poorly understood. We report the results of a
meta-analysis across 29 genome-wide association studies, including a total of 23 285
migraine cases and 95 425 population-matched controls. We identified 12 loci associated
with migraine susceptibility (P < 5 × 10−8). Five loci are new (near AJAP1 on 1p36, near
TSPAN2 on 1p13, within FHL5 on 6q16, within c7orf10 on 7p14, and near MMP16 on
8q21). Three of these loci were identified in disease subgroup analyses. Brain tissue eQTL
analysis suggests potential functional candidate genes at four loci: APOA1BP, TBC1D7,
FUT9, STAT6, and ATP5B.
Recently, significant progress has been made in the identification of common genetic
variants associated with migraine susceptibility through genome-wide association (GWA)
studies of clinic-based migraine with aura (MA) patients1, migraineurs from the general
population2,3, and clinic-based migraine without aura (MO) patients4. To further elucidate
the genetic susceptibility of migraine, we performed a meta-analysis of 23 285 individuals
with migraine from 29 clinic- and population-based studies (Fig. 1, Supplementary Fig. 1,
Supplementary Note). These include 5 175 cases from five clinic-based patient collections,
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smatched to 13 972 population-based controls (Supplementary Table 1), as well as 18 110
cases from 14 population-based studies and 81 453 migraine-free or control individuals from
the same studies (Supplementary Table 2). Results from GWA studies of the five clinic-
based collections1,4 and four of the population-based collections2,3 have been previously
reported (Supplementary Fig. 2).
In addition to the primary meta-analysis using all available genotype data, three subgroup
analyses were performed in those cohorts where sufficient additional clinical information
was available (Supplementary Table 3). The first two subgroups consisted of migraine cases
fulfilling the International Headache Society diagnostic criteria5 for either MA or MO. The
third subgroup included only the clinic-based samples, under the hypothesis that they
represent a group of migraineurs more enriched for severe migraines than cases identified
from the general population.
Results from the primary meta-analysis and the three subgroups identify 142 single
nucleotide polymorphisms (SNPs), at a total of 12 loci, to be significantly associated with
migraine susceptibility (Table 1, Supplementary Fig. 3,4). Eight of those loci contain SNPs
that lie within a known transcript. In addition, 1 168 SNPs at 134 loci (Supplementary Table
4) showed suggestive association to migraine, again combining the primary analysis and the
three subgroup analyses. The single most significant P value overall was observed for
rs11172113 in the primary analysis (P value 2.69 × 10−19; Fig. 2a, Table 1) at the LRP1
locus on 12q13.
Five of the 12 genome-wide significant loci are new (near AJAP1, near TSPAN2, FHL5,
c7orf10, and near MMP16), while seven confirm previously reported migraine loci
(PRDM162, MEF2D4, TRPM81,2, near TGFBR24, PHACTR14, ASTN24, and LRP12). All
seven previously reported loci seen in this study remained significant (all p < 6.25 × 10−3,
correcting for eight previously reported loci) in analyses that exclude samples used in
previous reports1,2,4 (Supplementary Fig. 5 and Supplementary Table 5). Among the newly
identified loci, two contain SNPs with significant association that are located within known
transcripts. On 6q16, FHL5 encodes a transcription factor that regulates cAMP responsive
elements CREM and CREB6, which play a role in synaptic plasticity7 and memory
formation8. The locus also overlaps KIAA0776, which encodes a hypothetical protein also
known as UFL1. On 7p14, mutations in c7orf10 have been found in phenotypically mild or
even clinically asymptomatic forms of glutaric aciduria type III9, a rare metabolic
abnormality leading to persistent excretion of glutaric acid.
The novel loci on 1p36, 1p13, and 8q21 are located outside known transcripts. On 1p36,
rs10915437 is located approximately 500 kb telomeric from AJAP1 and approximately
300kb centromeric from a gene cluster encoding the apoptosis-related proteins DFFB and
TP73 as well as centrosomal protein CEP104. AJAP1 is expressed in brain (Supplementary
Fig. 6) and has been associated with tumor invasion and regulation of metalloproteinase
activity10. On 1p13, rs12134493 is located 87 kb 5′ of TSPAN2, a member of the tetraspanin
family, encoding a cell surface protein that mediates signal transduction events involved in
the regulation of cell development, activation, growth and motility11. TSPAN2 has further
been shown to act as a regulator of metalloproteinase activity11. On 8q21, rs10504861 is
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slocated 200 kb telomeric from matrix metalloproteinase MMP16. Members of the
metalloproteinase family are widely expressed in human tissues and are involved in the
breakdown of extracellular matrix in normal physiological processes. Notably, the protein
encoded by MMP16 (MT-MMP2) cleaves LRP112, encoded by a previously reported
migraine gene2. In addition, MMP16 has recently been shown to be involved in basal NgR1
(Nogo-66 receptor) shedding in cortical neurons, thereby increasing axonal and synaptic
plasticity13.
Four of the twelve loci (near AJAP1, near TGFBR2, PHACTR1, near MMP16), including
two of the novel associations, were identified exclusively in the subgroup analyses (Table 1
and Supplementary Table 4). Two of the loci (rs9349379 in PHACTR1 on 6p21, and
rs10504861 near MMP16 on 8q21) reached genome-wide significance only in MO, while no
SNPs reached genome-wide significance in MA (Fig. 2c, d). The lowest P value in MA was
with SNP rs7015657 (p = 7.88 × 10−8), which is located approximately 582 kb 3′ from
GFRA2, a member of the glial cell line-derived neurotrophic factor family.
A similar subgroup analysis was performed in only those samples that originate from
specialized migraine clinics. Two loci with suggestive association in the primary analysis,
rs6790925 (near TGFBR2) and rs6478241 (ASTN2), reached genome-wide significance in
the clinic-based subgroup (Table 1 and Supplementary Tables 6,7). All of the 12 genome-
wide significant loci associated with migraine had larger estimated effect sizes in the clinic-
based subgroup compared to the primary (All) analysis (Supplementary Table 6, 7). A two-
tailed binomial test shows the chance of observing larger effects at all 12 loci is significantly
different from that expected by chance (P = 4.88 × 10−4). Among all reported loci (P <1 ×
10−5), only the clinic-based group showed a number of associated SNPs with higher effect
sizes (OR > 1.2) at low frequency (MAF < 0.05; Supplementary Fig. 7). Thus, clinic-based
migraine samples may represent a promising subgroup to help prioritise loci in the search
for low frequency variants with moderate effects. Overall, among the 146 loci identified,
twice as many have causative minor alleles over protective ones (with the ratio increasing
towards the lower minor allele frequencies).
To explore the biological context for the identified loci we examined the properties of the
most proximal genes to the 12 genome-wide significant top SNPs (Table 1). In expression
data from 55 269 samples profiled using the Affymetrix HG-U133 Plus 2.0 microarray
(including 1 990 brain and 384 endothelial samples), 11 of the 12 genes nearest to the
identified loci (all except FHL5) were at least moderately (>20% of samples of the tissue
showing a normalized log2 expression value greater than 6; see Methods) expressed in
disease-relevant brain regions (Supplementary Fig. 6). In contrast, only TGFBR2 and
MEF2D show moderate or greater expression in the endothelial samples. Possibly reflecting
known co-morbidity between migraine and cardiovascular disease14, two of the 12 most
proximal genes (TGFBR2 and PHACTR1) have also been associated with cardiovascular
traits: TGFBR2 mutations have been reported to cause monogenic Marfan’s syndrome15 and
to be involved in abdominal aortic aneurysms16, while PHACTR1 is associated with early
onset myocardial infarction17. TSPAN218, MEF2D19, TRPM820, TGFBR221, PHACTR122,
MMP1623, ASTN224, and LRP125 have been suggested to have functions in synaptic
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sformation or regulation; PRDM16 has been linked to oxidative stress response, and AJAP1
in maintaining tissue borders (Supplementary Fig. 8).
To identify possible non-proximity based genes underlying these associations, we examined
eQTL data among 394 samples of brain tissue from the North American Brain Expression
Consortium and the UK Brain Expression Consortium. Among the 12 regions with
significant association to migraine, four were found to contain significant eQTLs (see
Methods) among the SNP-probe pairs within the tested brain samples (four in the frontal
cortex, one in the cerebellum; Table 2). On chromosome 1, rs12136718 is an eQTL for
APOA1BP, rather than the gene closest to it, MEF2D. APOA1BP is widely expressed and is
potentially linked with cholesterol efflux from cells26. On chromosome 6, rs35128104 is an
eQTL for FUT9, encoding α1,3-fucosyl transferase IX. The FUT9 enzyme synthesizes the
Lewis X (Lex) carbohydrate structure, which has been implicated in neurite outgrowth in
several types of brain neuronal cells27-29. At the chromosome 12 locus, two different eQTLs
in brain tissue were found within the peak, for STAT6 (rs4559) and for ATP5B
(rs113953523), the former at a very robust P-value (2.16 × 10−22). The STAT genes are
known for transducing activation signals to transcription factors in macrophages30, and
STAT6 phosphorylation has recently been shown to sense oxidative stress in astrocytes
resulting in prostaglandin release31. A second eQTL gene at the same locus, ATP5B, is the β
subunit of the mitochondrial ATP synthase, but a potential specific role in neuronal or
vascular cells is not known. Finally, on chromosome 6, rs9349379 is an eQTL in cerebellar
tissue for TBC1D7, that potentially down regulates the tuberous sclerosis gene, TSC1,
through a positive regulation of the mTOR-signalling pathway32. In the central nervous
system, TSC1/2 signalling contributes to neural connectivity via its multi-faceted roles33.
Based on the available data it is not possible to decide whether a gene identified by the
eQTL analysis or the gene closest to the strongest positional association is the most relevant
gene contributing to migraine pathogenesis.
In a hypersensitivity site analysis, associated SNPs in the migraine loci were found to occur
significantly more often in DNAse I hypersensitivity sites in a number of tissues
(Supplementary Fig. 9). This suggests that the loci associated with migraine are enriched for
actively transcribed regions, supporting a regulatory role for the variants. Both neuronal and
vascular tissue types carry an enriched set of sites within the detected loci. In addition,
querying the RegulomeDB (see URLs) showed that several of the associated SNPs were
found to overlap directly with known transcription factor binding motifs (Supplementary
Table 8).
The number of significantly associated loci is still modest to form a broad understanding of
the disease susceptibility, and any proposed functional hypothesis from the identified loci
must thus be taken with caution. Some functional hypotheses could be inferred from the
results of this study, as the majority of the identified loci harbour genes that can be linked to
neuronal function.
The eQTL analysis further supported that regulatory effects in brain tissue may underlie
several of the association signals. However, the lack of replication across brain regions
Anttila et al. Page 4
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ssuggests that our ability to use the eQTL data to pinpoint the functionally most significant
gene within the locus is limited.
The observed difference between the number of significant loci in the MO and MA groups
(6 vs 0, respectively; Fig. 2c, d) despite reasonably similar sample sizes was somewhat
unexpected. MA has been shown to have a considerably higher heritability estimate and
sibling recurrence risk than MO (3.8 vs 1.9), and has thus been considered to be the more
heritable of the two common migraine types34. One possible explanation could be that the
genetic susceptibility to MA is mediated more by rare variants with larger effect sizes,
although this remains speculative. Another explanation for the difference may be a higher
degree of heterogeneity among the MA cases (due to genetically distinct subgroups, for
example). No common variants specifically predisposing to aura were identified by this
study (the lowest observed P-value was p = 7.88 × 10−8).
In summary, we conducted a large migraine meta-analysis and identified 12 loci associated
with migraine susceptibility, including five loci not previously associated with migraine, as
well as 134 additional suggestive loci. An eQTL analysis of brain tissue highlighted a
further five genes potentially implicated in migraine susceptibility. Two of the 12 loci were
observed only in the clinic-based sample group, possibly suggesting more specificity to
severe migraine headache, and two only in the MO group. Seven previously reported loci for
migraine susceptibility were replicated in independent samples in this study. The difference
in the number of identified loci and the strength of association suggest that the genetic
background of MA is considerably less influenced by common variants than that of MO,
contrary to previous expectations. Finally, while pathway analysis of the 146 loci showed no
concentration in any particular pathway or tissue, eight of the 12 identified loci are located
in or immediately outside genes with known function in synaptic or neuronal regulation and
several of them exert regulatory control on one another.
Methods
Overall study design
For this meta-analysis, we used SNP marker data from 23 285 cases and 95 425 controls of
European descent from 29 studies, including five clinic-based studies compared to
population-matched control samples with unknown migraine status, as well as 14 entirely
population-based cohorts. Four of the population-based cohorts (the B58C, NFBC, Young
Finns and FinnTwin; see Supplementary Note for further details) were birth cohorts. The
datasets for the meta-analysis included previously genotyped genome-wide association
(GWA) study data from migraine-specific studies by the International Headache Genetics
Consortium (see URLs) studies and the Women’s Genome Health Study, as well as a
number of pre-existing population-based GWA studies (for complete list of references, see
Supplementary Table 2). Local research ethics committees approved the individual studies,
and informed consent was obtained from all participants when necessary (see the
Supplementary Materials for full details of ethics and consent procedures for each study).
Additional details on sample recruitment and phenotypes and summary details for each
collection are given in the Supplementary Note and in Supplementary Tables 1 and 2.
Genome-wide SNP genotyping was performed independently in each cohort with the use of
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svarious standard genotyping technologies, and imputed for each study with reference to
HapMap release 21 or 22 CEU phased genotypes35.
Study phenotypes
The primary phenotype analysed was migraine of any type, regardless of source. This was
followed by a subgroup analysis consisting of 1) analysing only the clinical samples, 2) only
samples satisfying criteria for MA, and 3) for MO. Population-based samples were not
analysed genome-wide as a subgroup, due to forming 78% of cases and 85% of controls in
the main analysis, but associations were calculated for the significant SNPs for comparative
purposes. In the clinical cohorts, headache specialist has assigned a migraine diagnosis
based on direct or telephone interview or through the use of an extensive questionnaire. For
the population studies, migraine status for individuals in a study sample has been determined
by a questionnaire (see Supplementary Note).
Statistical analysis of GWA study data
Each study contributed summary statistic data from an association analysis performed using
a frequentist additive model based on an expected allelic dosage model for SNP markers,
adjusting for gender (using either SNPTEST or ProbABEL [see URLs]). SNPs were filtered
on per-study level based on inclusion criteria of MAF>0.1% and imputation quality
measures of IA > 0.6 (IMPUTE 236) or r2 > 0.3 (MACH37). Four of the included studies
contain novel genotyping (HUNT) or imputation (the Finnish, German and Dutch MA
studies and HUNT). In the meta-analysis, combined association data for ~2.3 million
imputed and genotyped autosomal SNPs were analysed in a fixed-effects model using
GWAMA. At this stage, SNPs with a heterogeneity coefficient I2 exceeding 75% or
presence in only four or fewer studies were filtered out. In the meta-analysis, there was little
evidence for population stratification at the study level (each genomic inflation factor λ≤
1.1), though moderate inflation was observed at the meta-analysis level (λ = 1.15;
Supplementary Fig. 4). For estimating genome-wide significance, we used the commonly
accepted threshold of 5 × 10−8 for primary loci 38, and 1 × 10−5 for secondary loci, in
accordance with the reporting threshold for the GWAS catalog39. At secondary loci, to limit
spurious associations, at least two SNPs were required to pass the significance threshold
within a 50kb window. We also estimated the robustness of this threshold using the false
discovery rate method of Benjamini & Hochberg40, showing that the P value threshold
corresponding to FDR<0.05 was 2.33 × 10−5. The quantile-quantile plot (Supplementary
Fig. 4) of the meta-analysis P values showed a marked excess of association signals well
beyond those expected by chance below the suggestive reporting threshold. The significant
loci were visualized using the LocusZoom interface41. For the heterogeneity analyses for
migraine type, due to shared controls in some of the sets, the available study samples were
divided into as equally-sized groups in terms of effective study size as possible, and then the
data was analysed using the gender heterogeneity analysis method 42 (–sex option) of
GWAMA43, with a dummy variable coding for MA and MO instead of gender. For the
heterogeneity analyses for gender, the same method was used to compare P values from
males-only and females-only analyses.
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sPathway analyses
MAGENTA - The MAGENTA software44 was used to conduct an analysis to evaluate
whether P values for association with migraine are enriched to particular biological
networks, using pathway lists from GO, PANTHER, INGENUITY, KEGG, REACTOME
and BIOCARTA. In the gene set enrichment analysis, P values were estimated via 10,000
permutations of genes evaluated at 75th FDR percentile (due to assumption of high
polygenicity), manually corrected to account for FDR across all pathway sets. DAPPLE -
Using a refined database of high-confidence protein-protein interactions (InWeb45,46) we
used DAPPLE 47 to assess the amount of physical interactions connecting the genes within
50 kb of the 146 reported migraine loci, as well as an analysis of only the 16 proteins from
the 12 genome-wide significant loci. Both direct and indirect (through 1st order common
interaction partners) were measured and compared to a random expectation over 10,000
permutations, and the resulting network was plotted. GRAIL - The GRAIL web interface 48
was used to explore similarities in published PubMed articles (August 2012 freeze), using
data from HapMap release 22 CEU and gene size correction set to on. From the GRAIL
results, only genes with significant (P value<0.05) are shown, and the list of similar genes
was capped at genes within the top 200 highest ranks.
Overlap with DNAse I hypersensitivity sites
The positions of SNPs from migraine-associated loci were overlapped with DNase 1
‘hotspot’ regions from the ENCODE project that mark generalized chromatin accessibility
mapped for each of 125 diverse cell lines and tissues49. To assess the significance of overlap
for the set of SNPs as a whole, 100 background sets of SNPs were chosen from the genome
so that each migraine associated SNP was matched in each set by a SNP within the same
decile for minor allele frequency, distance to the nearest transcription start site and GC
content of the 100 base region surrounding the SNP. The background SNP sets were
overlapped with the DNase 1 hotspots, and the enrichment for overlap with the migraine
associated SNP set expressed as the Z score relative to the distribution of background SNP
set overlaps on a per cell line basis. In addition migraine associated SNPs were analysed for
other overlap with ENCODE data including transcription factor motifs using RegulomeDB
(http://regulome.stanford.edu)50.
Tissue-based gene expression analysis
For the tissue analysis, a microarray-based analysis of gene expression was performed on a
dataset of 55 269 samples in the Gene Expression Omnibus (GEO) database that were
measured on the Affymetrix U133 Plus 2.0 Array. Each sample in the raw expression data
was first linearly transformed using a modified invariant set normalization method51 on a set
of eighty control genes with stable expression on U133 Plus 2.0. The expression data was
log2 transformed to stabilize the variance and expression distribution. Finally, the data were
quantile-normalized52 to match the expression distribution of each sample. Expression
values for genes with multiple probe sets were calculated by taking the median value of all
probe sets for that gene. Following normalization, a log2 expression value of 4 is considered
baseline and log2 expression values greater than 6 are considered expressed. Sample
annotations were curated based on GEO descriptions provided by depositors. To account for
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svariation in the number of samples representing each tissue in the dataset, expression of a
gene was plotted to show the fraction of samples of a tissue that exceeds a log2 expression
value of 6, with higher fractions indicating more ubiquitous expression in the tissue in
question.
eQTL analysis
Based on the meta-analysis results for association with migraine, 146 regions of interest
were queried against the expression quantitative trait loci (eQTL) results from the North
American Brain Expression and UK Brain Expression Consortium studies (GEO #
GSE36192, dbGaP # phs000249). These eQTL results are based on Cerebellum and Frontal
Cortex tissue mRNA expression levels from 394 human subjects (see Supplementary
methods). Of the 146 associated regions 134 were represented in the eQTL analysis. Within
these regions 831 mRNA expression traits and 222 668 cis SNP/expression trait pairs were
considered in Cerebellum and 864 mRNA expression traits and 230 660 cis SNP/expression
trait pairs were considered in within the Frontal Cortex. 45 SNPs within the migraine
associated loci were found to have significant correlation (evaluated at FDR-corrected
threshold; 0.0001668 for frontal cortex and 0.0002187 for cerebellum) with the expression
of 12 mRNA transcripts in both the Cerebellum and the Frontal Cortex. A more detailed
methods description can be found in Supplementary Materials. The extent of linkage
disequilibrium between SNPs associated with migraine and the SNPs in the tested eQTL
SNP-probe pairs was evaluated using SNAP (see URLs).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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sFigure 1. Description of the studies comprising the International Migraine Genetics Meta-
analysis Consortium, and their sample contributions to each analysis
Each coloured box corresponds to one analysed phenotype and lists the total number of
cases and controls, as well as the sample contributions of individual cohorts. Participation in
each analysis depended on the availability of the data in question and the recruitment
method.
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sFigure 2. Manhattan plot of the results of the meta-analysis
Results of the meta-analysis of all migraine cases, of any migraine subtype or recruiting
method, versus all available controls, adjusting for gender. Red dots indicate SNPs with
significant (< 5 × 10−8) P values.
A) All migraine (23 285 cases, 95 425 controls)
B) Clinic-based studies only (5 175 cases, 13 972 controls)
C) Migraine with aura (5 118 cases, 74 239 controls)
Anttila et al. Page 15
Nat Genet. Author manuscript; available in PMC 2014 June 02.
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
s
 
E
u
r
o
p
e
 
P
M
C
 
F
u
n
d
e
r
s
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
sD) Migraine without aura (7 107 cases, 69 427 controls)
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